SCHEMBL5156963

SCHEMBL5156963

O=C1CSC(c2ccc(C(F)(F)F)c(F)c2)N1CCc1ccc2c(c1)OCO2

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
MGAM O43451 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KCNA5 P22460 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CACNA1B Q00975 2/20 0.43
USP2 O75604 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
DPP4 P27487 3/20 0.42
AR P10275 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152808 0.80 MAPT (0.53) ALDH1A1SMN1; SMN2GAAL3MBTL1KCNA5
SCHEMBL5152128 0.79 ALDH1A1 (0.48) ALDH1A1MGAMSMN1; SMN2GAAL3MBTL1
SCHEMBL5151382 0.79 ALDH1A1 (0.54) ALDH1A1MGAMSMN1; SMN2GAAL3MBTL1
SCHEMBL5152818 0.79 GAA (0.73) SMN1; SMN2GAAL3MBTL1KCNA5KDM4E
SCHEMBL5149502 0.78 MGAM (0.56) ALDH1A1MGAMSMN1; SMN2GAAL3MBTL1
SCHEMBL5151414 0.78 ACHE (0.56) ALDH1A1MGAMSMN1; SMN2GAAL3MBTL1
SCHEMBL5155489 0.77 ALDH1A1 (0.56) ALDH1A1MGAMSMN1; SMN2GAAL3MBTL1
SCHEMBL5152753 0.75 PTGS1 (0.43) SMN1; SMN2KCNA5CACNA1B
SCHEMBL5155012 0.75 ACHE (0.47)
SCHEMBL5152878 0.75 PTGS1 (0.43) ALDH1A1SMN1; SMN2KCNA5MAPTCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 ALDH1A1 3381/4885MGAM 2524/4885SMN1; SMN2 2615/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885MGAM 3677/4885SMN1; SMN2 1195/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I ALDH1A1 1370/4885MGAM 3677/4885SMN1; SMN2 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.